Ads
related to: prednisone use in prostate cancer
Search results
Results From The WOW.Com Content Network
It is used in combination with prednisolone or another medicine prednisone, which is converted into prednisolone. [2] In the United States, niraparib/abiraterone is indicated, in combination with prednisone, for adults with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer, as determined by an FDA-approved test.
Abiraterone acetate is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer). [2] [6] [5] [4] This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor antagonists.
CYP17A1 inhibitors, such as abiraterone acetate, are primarily used in the treatment of prostate cancer. These drugs reduce androgen levels, which helps to slow the progression of prostate cancer in patients with castration-resistant prostate cancer. [4]
Radiation therapy is commonly used in prostate cancer treatment. It may be used instead of surgery or after surgery in early-stage prostate cancer (adjuvant radiotherapy). Radiation treatments also can be combined with hormonal therapy for intermediate risk disease, when surgery or radiation therapy alone is less likely to cure the cancer.
In 2011, the FDA approved the CYP17A1 inhibitor, abiraterone, which contains a steroidal scaffold that is similar to the endogenous CYP17A1 substrates, with prednisone for the treatment of castration-resistant prostate cancer. Abiraterone is structurally similar to the substrates of other cytochrome P450 enzymes involved in steroidogenesis, and ...
The research, conducted by the Beatson West of Scotland Cancer Centre, has been welcomed by ex-soldier, John Culling, 64, who was diagnosed with an aggressive form of prostate cancer in 2019.
Ads
related to: prednisone use in prostate cancer